

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number
Filing Date October 24, 2003
First Named Inventor Bohannon, Robert C.
Group Art Unit
Examiner Name
Attorney Docket Number 018877-000122US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
/KAC/	AA	4,235,864		Kaul et al.	11-25-1980	
/KAC/	AB	4,620,977		Strahilevitz	11-04-1986	
/KAC/	AC	5,773,003		Swain et al.	06-30-1998	
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
/KAC/	BA	PCT	WO 92/03163	A1	Cerny	03-05-1992		
	BC							
	BD							
	BE							

Examiner Signature

/Karen A. Canella, Ph.D./

Date Considered

04/30/2007

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60067997 v1

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **2**

Complete if Known

Application Number	
Filing Date	October 24, 2003
First Named Inventor	Bohannon, Robert C.
Group Art Unit	
Examiner Name	
Attorney Docket Number	018877-000122US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/KAC/ ↓ ↓ ↓ ↓ ↓ ↓	A1	Bagasra, O., et al., "A potential vaccine for cocaine abuse prophylaxis," Immunopharmacology, 23:173-179 (June, 1992)	
	A2	Carrera et al., "Suppression of psychoactive effects of cocaine by active immunization," Nature, 378:727-730 (December, 1995)	
	A3	Gallacher, G., "A potential vaccine for cocaine abuse prophylaxis?" Immunopharmacology, 27:79-81 (February, 1994)	
	A4	Okawa, Y., et al., "Production of anti-peptide specific antibody in mice following immunization with peptides conjugated to mannan," Journal of Immunological Methods, 149:127-131 (1992)	
	A5	Colburn, W.A., "Specific Antibodies and Fab Fragments to Alter the Pharmacokinetics and Reverse the Pharmacologic/Toxicologic Effects of Drugs," Drug Metabolism Reviews, 11(2):223-262 (1980)	
	A6	Jain, R.K., "Vascular and interstitial barriers to delivery of therapeutic agents in tumors," Cancer and Metastasis Reviews, 9:253-266 (1990)	
	A7	El-Shazly, M.O., et al., "Histopathological Study into Side-Effect Toxicity of some Drugs used in Treatment of Cancer," Arch. Exper. Vet. Med., Leipzig 43:319-326 (March 1989)	
	A8		
	A9		
	A10		
	A11		

60067997 v1

Examiner
Signature

/Karen A. Canella, Ph.D./

Date
Considered

04/30/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60067997 v1